| News

Opterion Health AG moving to Muttenz

22.01.2021

Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from the local life sciences ecosystem. Following a significantly oversubscribed bridge financing round, Opterion was able to raise a total of 8.4 million euros for its innovative peritoneal dialysis solution.

biotechnology

Opterion Health AG has announced its intention to vacate its current headquarters in Sarnen in the canton of Obwalden and move to Muttenz in the canton of Basel-Landschaft. The new location is situated in The 5th Floor coworking space. The aim of the move is for Opterion to become part of the Life Sciences ecosystem in the Basel region, the company writes in a press releaseBasel Area Business & Innovation, the investment and innovation promotion agency for the region, supported the preclinical company in its preparations for the move to Muttenz.

“We are excited about our relocation to the canton of Basel-Landschaft and that Opterion will now become part of the Basel Area life sciences ecosystem”, says Ricardo Cordero, Vice Chairman of Opterion. He adds: “The support we received from the Basel Area Business & Innovation team to find the best location for Opterion was outstanding. We are truly thankful for this since it saved us much effort and cost.”

The announcement from Opterion comes on the back of a successful bridge financing round, which was reported to be 40 percent oversubscribed. As result, the company was able to raise 8.4 million euros. As the press release explains further, this amount was obtained from a small group of private and institutional investors based in Switzerland and Germany.

Opterion is currently focusing on the preclinical phase for a novel peritoneal dialysis (PD) solution. According to information from the company itself, this is set to “revolutionize” the market and replace the gold standard product of the current market leader.

“The PD market has not seen any significant innovation for over two decades”, explains Guido Grentzmann, founder and CEO/CSO of Opterion. He goes on to add that the solution developed by Opterion not only delivers better therapeutic outcomes, but also offers improved quality of life and survival rates for dialysis patients. In addition, more than 45% of dialysis patients also suffer from diabetes. For this reason, the glucose-free dialysis solution from Opterion represents a “much-needed innovation”. Moreover, a great deal more patients will now be in a position to have dialysis treatment at home.

The “very successful” closing of the financing round means that Opterion will be “in the position of being very comfortably financed for the next two years”, explains CFO Andreas Schmidt in the press release, before adding: “This gives us the opportunity to execute our scientific as well as manufacturing plans and prepare for Phase I with full speed”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.